Kelly Paul's most recent trade in Relmada Therapeutics Inc was a trade of 400,000 Stock Option (right to buy) done . Disclosure was reported to the exchange on June 26, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Relmada Therapeutics Inc | Paul Kelly | Director, Chief Operating Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jun 2025 | 400,000 | 400,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director, Chief Operating Officer | Purchase of securities on an exchange or from another person at price $ 0.43 per share. | 16 May 2025 | 200,000 | 412,295 (2%) | 1% | 0.4 | 86,060 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Purchase of securities on an exchange or from another person at price $ 2.59 per share. | 09 Sep 2024 | 25,000 | 212,295 (1%) | 0% | 2.6 | 64,750 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Other type of transaction at price $ 0.00 per share. | 24 May 2024 | 43,700 | 65,672 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 24 May 2024 | 43,700 | 109,372 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Kelly Paul | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Dec 2023 | 65,672 | 65,672 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 25 May 2023 | 92,958 | 150,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 56,000 | 94,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 19,600 | 130,400 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 18,000 | 132,000 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 31 Dec 2022 | 6,400 | 41 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Dec 2022 | 57,042 | 57,042 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 04 Apr 2022 | 10,000 | 197,295 (1%) | 0% | 3.2 | 32,400 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 04 Apr 2022 | 10,000 | 20,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 30.04 per share. | 04 Apr 2022 | 10,000 | 187,295 (1%) | 0% | 30.0 | 300,395 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 03 Jan 2022 | 20,000 | 30,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 03 Jan 2022 | 20,000 | 187,295 (1%) | 0% | 3.2 | 64,800 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Dec 2021 | 117,530 | 117,530 | - | - | Stock Option (right to buy) | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 Mar 2021 | 5,000 | 50,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 09 Mar 2021 | 5,000 | 172,295 (1%) | 0% | 3.2 | 16,200 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.42 per share. | 09 Mar 2021 | 3,388 | 168,907 (1%) | 0% | 35.4 | 119,995 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 36.33 per share. | 09 Mar 2021 | 1,612 | 167,295 (1%) | 0% | 36.3 | 58,556 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 24 Feb 2021 | 5,000 | 172,295 (1%) | 0% | 3.2 | 16,200 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 24 Feb 2021 | 5,000 | 55,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 34.64 per share. | 24 Feb 2021 | 2,463 | 167,403 (1%) | 0% | 34.6 | 85,315 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 33.67 per share. | 24 Feb 2021 | 2,429 | 169,866 (1%) | 0% | 33.7 | 81,775 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.58 per share. | 24 Feb 2021 | 108 | 167,295 (1%) | 0% | 35.6 | 3,843 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Feb 2021 | 5,000 | 20,000 | - | - | Warrants | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 6.00 per share. | 16 Feb 2021 | 5,000 | 167,295 (1%) | 0% | 6 | 30,000 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 08 Feb 2021 | 3,569 | 60,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 08 Feb 2021 | 3,569 | 165,864 (1%) | 0% | 3.2 | 11,564 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.29 per share. | 08 Feb 2021 | 2,069 | 162,295 (1%) | 0% | 35.3 | 73,005 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 08 Feb 2021 | 1,500 | 164,364 (1%) | 0% | 35.0 | 52,560 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 15,000 | 66,415 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 01 Feb 2021 | 15,000 | 162,295 (1%) | 0% | 3.2 | 48,600 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Feb 2021 | 2,346 | 64,069 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 01 Feb 2021 | 2,346 | 164,641 (1%) | 0% | 3.2 | 7,601 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.04 per share. | 01 Feb 2021 | 2,315 | 162,295 (1%) | 0% | 35.0 | 81,118 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.00 per share. | 01 Feb 2021 | 31 | 164,610 (1%) | 0% | 35 | 1,085 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 27 Jan 2021 | 5,000 | 81,415 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 27 Jan 2021 | 5,000 | 152,295 (1%) | 0% | 3.2 | 16,200 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 32.89 per share. | 27 Jan 2021 | 2,988 | 147,463 (1%) | 0% | 32.9 | 98,275 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 31.69 per share. | 27 Jan 2021 | 1,844 | 150,451 (1%) | 0% | 31.7 | 58,436 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 33.40 per share. | 27 Jan 2021 | 168 | 147,295 (1%) | 0% | 33.4 | 5,611 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 22 Jan 2021 | 4,085 | 151,380 (1%) | 0% | 3.2 | 13,235 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 22 Jan 2021 | 4,085 | 86,415 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.43 per share. | 22 Jan 2021 | 1,800 | 149,580 (1%) | 0% | 35.4 | 63,774 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 3543.00 per share. | 22 Jan 2021 | 1,800 | 149,580 (1%) | 0% | 3543 | 6,377,400 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.27 per share. | 22 Jan 2021 | 1,300 | 147,980 (1%) | 0% | 35.3 | 45,851 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 35.16 per share. | 22 Jan 2021 | 685 | 147,295 (1%) | 0% | 35.2 | 24,085 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Sale of securities on an exchange or to another person at price $ 36.18 per share. | 22 Jan 2021 | 300 | 149,280 (1%) | 0% | 36.2 | 10,854 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Jan 2021 | 150,000 | 150,000 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 18 Aug 2020 | 22,000 | 90,500 | - | - | Options to purchase common stock | |
| Relmada Therapeutics Inc | Paul Kelly | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 3.24 per share. | 18 Aug 2020 | 22,000 | 149,121 (1%) | 0% | 3.2 | 71,280 | Common Stock |
| Relmada Therapeutics Inc | Paul Kelly | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 39.03 per share. | 18 Aug 2020 | 1,826 | 147,295 (1%) | 0% | 39.0 | 71,269 | Common Stock |